Event: IWWM-12 2024

0:03:23

IWWM 12 Slideshow

0:02:10

IWMF at the IWWM-12 (2024): with Dr Gareth Morgan

0:02:33

IWMF at the IWWM-12 (2024): with Professor Christian Buske

0:02:54

IWMF at the IWWM-12 (2024): with Dr Stephen Ansell

0:02:49

IWMF at the IWWM-12 (2024): with Dr Anne-Marie Becking and Dr. Wouter Verhaar

0:06:49

IWMF at the IWWM-12 (2024): with Dr Saemundur Rognvaldsson

0:01:51

IWMF at the IWWM-12 (2024): with Professor Shirley D'Sa

0:00:57

Using genomics to understand ibrutinib resistance in Waldenström's macroglobulinemia

0:02:18

Advice for treating Waldenström's macroglobulinemia in the second line

0:01:21

The role of chemoimmunotherapy in the era of targeted therapies for WM

0:05:22

IgM de-myelinating neuropathy as a complication of MGUS and WM

0:01:27

Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia

0:01:38

Multi-omics studies to understand the progression from premalignant states to WM

0:01:14

Managing AEs associated with bortezomib in the treatment of Waldenström's macroglobulinemia

0:01:32

The interaction between bone marrow stromal cells and tumor cells as a potential target in WM

0:01:05

Hyperviscosity syndrome as a complication in WM and its management with plasma exchange

0:01:47

Unmet needs in WM: managing high-risk disease, sequencing novel agents, & personalizing treatment

0:01:04

Immunotherapies in the future treatment landscape for Waldenström's macroglobulinemia

0:01:59

Novel targets and therapeutics being explored in Waldenström's macroglobulinemia

0:01:55

The diverse presentation of symptoms in patients with Waldenström's macroglobulinemia

0:01:42

The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53

0:01:28

Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM

0:01:32

The use of multi-omics to understand the progression from MGUS to WM

0:01:11

Multi-omic analysis in WM: progress being made and challenges that remain